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Abstract: Humans have developed effective survival mechanisms under conditions of nutrient
(and energy) scarcity. Nevertheless, today, most humans face a quite different situation: excess of
nutrients, especially those high in amino-nitrogen and energy (largely fat). The lack of mechanisms
to prevent energy overload and the effective persistence of the mechanisms hoarding key nutrients
such as amino acids has resulted in deep disorders of substrate handling. There is too often a
massive untreatable accumulation of body fat in the presence of severe metabolic disorders of energy
utilization and disposal, which become chronic and go much beyond the most obvious problems:
diabetes, circulatory, renal and nervous disorders included loosely within the metabolic syndrome.
We lack basic knowledge on diet nutrient dynamics at the tissue-cell metabolism level, and this adds
to widely used medical procedures lacking sufficient scientific support, with limited or nil success.
In the present longitudinal analysis of the fate of dietary nutrients, we have focused on glucose as
an example of a largely unknown entity. Even most studies on hyper-energetic diets or their later
consequences tend to ignore the critical role of carbohydrate (and nitrogen disposal) as (probably) the
two main factors affecting the substrate partition and metabolism.
Keywords: diet; energy metabolism; glucose; body energy interchanges; inter-organ energy
relationships; handling of dietary lipids; energy storage; dietary protein as energy substrate; disposal
of excess nitrogen
1. Introduction: Diet and Its Use in Energy Metabolism
At present, two main lines of study focus on metabolic acquisition, distribution and use of food
energy to maintain efficiently human body functions. (1) The analysis of foods and diets, which
largely uses centuries-old methodologies, and its subject of study is the relationship to diet of the
body in relation to health and disease. (2) The analysis and function of cell and molecular effects of
diet has developed during the last 8–9 decades, using the high pace of methodological advances and
accumulated knowledge at the molecular and cellular level, with important inroads into the regulation
of the cell, organ, and body homeostasis. Unfortunately, both lines run parallel, and there is not enough
shared—connecting—knowledge to use the enormous amount of knowledge accumulated to help
explain the direct relationships of dietary components with metabolic modulation and regulation,
despite the paramount importance of this nexus. The complexity (and variability at all levels) or the
problem hampers any approach to the health (and survival) problems related to diet.
In this focused review, we intend to present a few critical questions that may help to bridge
the gap between these two lines. In most cases, the lack of hard research data is surprising [1].
The excessive narrowness of these study goals is even more severe [2]. The forfeiting of a large
mass of knowledge accumulated just before the present century [3], and limited use of quantitative
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approaches [4], effectively breaks the continuum of research and knowledge that has brought us to the
scattering of “modern” discoveries [5], in addition to the unjustified predominance of easily available
(despite their complexity) recent techniques to obtain knowledge (and publishable material).
Because of its central role in metabolism (and physiology) and its assumed predominance on diet,
we focused this lineal study on glucose, its dietary sources, its metabolic utilization, regulation and
–specially– on its real “essentiality” and required supply.
2. Why Glucose?
All heterotrophs need to periodically ingress chemical substrates to oxidize and extract enough
energy to sustain their survival against predators and the scarcity of nutrients, and to allow for the
maintenance of the species and the intergenerational transmission of information. This is a basic
biological rule, from which, obviously, humans and other placental mammals cannot escape. Today,
the methodology to produce, prepare, and ingest a variety of foods is enormous, but we continue to
retain most of the essential metabolic pathways inherited from our archaeal ancestors [6]. In the end,
the main—and overwhelming—process to obtain usable chemical energy is photosynthesis, which
produces D-glucose, and from that, an enormous number of organic molecules which later we use to
build, protect, and provide energy to maintain our structures and functions.
Glucose is far from being a “perfect” substrate [7,8] in the same way as oxygen [9] is, but both are
widely available, and coevolution allows us to continue using them just for biologic economy reasons.
Both are materials dangerous for cells to handle, but we use glucose since we are geared to its massive
consumption because of its ubiquity for the essential fact that glucose is produced by autotrophs as
basic tool for their own metabolism, thus “providing” us with it as a main energy staple.
We often tend to forget that glucose is a powerful reducing agent. It occurs, in part, because under
physiological conditions its high reactivity is less patent. Glucose in physiological media is found in
essentially five different forms, four of them non-reducing, cyclical, with an internal hemiacetalic bond
(isomers α- and β- of glucopyranose or glucofuranose), and the “open” reactive aldehyde form [10]
(Figure 1). These molecular species are maintained in equilibrium, which favor the predominance of
the α- and β-glucopyranose forms [11]. They interconvert spontaneously at a relatively slow rate,
which can be accelerated by the enzyme mutarotase [12]. These changes necessarily require going
through the intermediate step of open aldehyde form [13]; during this brief period of high reactivity,
glucose may combine with amines (i.e., in proteins), initially forming Schiff bases, but can bind also to
a number of other molecules [13]. In consequence, this bound glucose is “lost” as a substrate for energy
and growth, often becoming, instead, a hindrance to the stability and function of diverse proteins [14].
Most enzymes (and transporters) acting on glucose (and on some of its essential derivatives, such as
glucose-6P) require glucose to be in the β-glucopyranose form [15], favoring its priority utilization
because is in this form when the proximity of the -OH in C1 is closer to the C4-C5 pair, allowing the
oxidation of the chain from the anomeric carbon. This selectivity, however, produces delays in glucose
availability through the interconversion of (mainly) the α-isomer, predominant in plasma [11,13],
that is non-usable “directly” in a number of metabolic processes. This limits the real-time access to
glucose and thus its truly physiological concentration [10]. This difficulty has not been metabolically
circumvented through evolution and has been massively ignored from the methodological point of
view by researchers, as proven by the common but only approximate quantitative specific analysis of
glucose using enzymatic methods [11].
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Glucose, however, has considerable advantages as a primary energy-substrate source: it can be 
easily converted in two 3C fragments even under anaerobic conditions (via the classic Embden–
Meyerhoff pathway), well preserved along evolution [6]. This quality is seldom recognized, 
especially considering the growing awareness on the perils of oxidative free radicals generated from 
oxygen metabolic interventions [9,16].  
3. The 3C Fragments, the World Around Pyruvate 
Splitting one 6C unit (i.e., glucose) yields a variety of (essentially) 3C molecules: pyruvate, L-
lactate, glycerol, alanine, serine, and phospho-enol-pyruvate (PEP), used for energy or synthetic 
pathways. 3C fragments are also generated from a number of key pathways in addition to straight 
glycolysis: the pentose-phosphate pathway, hexosamine metabolism, the Leloir (galactose) pathway, 
the catabolism of fructose and other monosaccharides as substrates, the incorporation of glycerides-
glycerol, lactate, and a number of amino acid hydrocarbon skeletons. Not all three-carbon metabolites 
can be included in this 3C list. The clearest examples are propionate (yielding succinyl-CoA, see 
Section 7) and D-Lactate, a significant component of bacterial fermentation (including our 
microbiota), found in some foods. Its degradation is difficult [17] but does not proceed directly via 
pyruvate. In this review, we will reserve the term “lactate” for L-lactate as in most metabolic studies. 
Pyruvate is the key 3C fragment from which the core of intermediary metabolism establishes the 
use of diet (or reserves/turnover) substrates (Figure 2), via direct oxidation for energy, used as 
building materials for biosynthesis or transport between pools (cell, organ, body) to achieve energy 
homeostasis and efficiency in metabolism. Pyruvate is also a main source of oxaloacetate (OAA) to 
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2019 [10].
Glucose, however, has considerable advantages as a primary energy-substrate source: it can
be easily converted in two 3C fragments even under anaerobic conditions (via the classic
Embden–Meyerhoff pathway), well preserved along evolution [6]. This quality is seldom recognized,
especially considering the growing awareness on the perils of oxidative free radicals generated from
oxygen metabolic interventions [9,16].
3. The 3C Fragments, the World around Pyruvate
Splitting one 6C unit (i.e., glucose) yields a variety of (essentially) 3C molecules: pyruvate, L-lactate,
glycerol, alanine, serine, and phospho-enol-pyruvate (PEP), used for energy or synthetic pathways.
3C fragments are also generated from a number of key pathways in addition to straight glycolysis: the
pentose-phosphate pathway, hexosamine metabolism, the Leloir (galactose) pathway, the catabolism
of fructose and other monosaccharides as substrates, the incorporation of glycerides-glycerol, lactate,
and a number of amino acid hydrocarbon skeletons. Not all three-carbon metabolites can be included in
this 3C list. The clearest examples are propionate (yielding succinyl-CoA, see Section 7) and D-Lactate,
a significant component of bacterial fermentation (including our microbiota), found in some foods.
Its degradation is difficult [17] but does not proceed directly via pyruvate. In this review, we will
reserve the term “lactate” for L-lactate as in most metabolic studies.
Pyruvate is the key 3C fragment from which the core of intermediary metabolism establishes
the use of diet (or reserves/turnover) substrates (Figure 2), via direct oxidation for energy, used as
building materials for biosynthesis or transport between pools (cell, organ, body) to achieve energy
homeostasis and efficiency in metabolism. Pyruvate is also a main source of oxaloacetate (OAA) to
regulate the TCA (tricarboxylic acid) cycle, i.e., the Krebs cycle (the second one) [18], or regenerate 6C
units via gluconeogenesis. These processes require a critical control of the crossing of the mitochondrial
membrane [19].
Pyruvate helps maintain the redox state of cytoplasm via interconversion to lactate (lactate
dehydrogenase) [20] as well as the transport through the cell membrane [21,22]. In any case,
the main drain of pyruvate is the formation of acetyl-CoA via oxidative decarboxylation by pyruvate
dehydrogenase [23]; this way, a 3C fragment becomes a 2C fragment and CO2.
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The regulation of glucose fate and circulating levels has been studied exhaustively, and it has 
been found that the alteration of these processes may cause serious harm to energy homeostasis. 
Glucose is strictly controlled by a huge number of regulatory agents, including insulin, 
glucocorticoids, glucagon, intestinal peptides, catecholamines, cytokines, testosterone, estrogens, etc. 
[24]. They regulate glucose splanchnic production [25] and utilization [26–28]. Glucose modulates the 
production and secretion of insulin [29] and, indirectly, its hepatic inactivation [30]. However, insulin 
resistance affects very directly glucose uptake and metabolism, because of changes in insulin tissue 
receptors and signaling [31]. On the other side, the 3C fragments (mainly pyruvate, lactate, glycerol) 
are regulated within the cells, but not as extensively as is glucose in their inter-organ relationships. 
3C substrates, such as lactate or glycerol can be easily taken up by a wide diversity of cells, even using 
less specific (or quite different) transport systems [32,33]. 
When the cell takes up lactate, it can immediately provide NADH in the cytosol, and then follow 
a number of diverse paths to provide C or energy (via conversion to 2C). In comparison, after a 
strongly regulated maintenance of its circulating levels, glucose is transported into the cell, converted 
to glucose-6P, and then it can be used for the production of 3C (and eventually 2C) through well-
regulated mechanisms. The main potential inconvenient for plasma-carried 3C (specifically lactate) 
is its charge (a proton) and its reduced state, which necessarily has to be corrected via production of 
cytosolic NADH, but this is the same problem glucose generates at the level of triose-P 
dehydrogenase. In any case, glycerol or pyruvate do not comport these hindrances. It is well known 
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The regulation of glucose fate and circulating levels has been studied exhaustively, and it has been
found that the alteration of these processes may cause serious harm to energy homeostasis. Glucose is
strictly controlled by a huge number of regulatory agents, including insulin, glucocorticoids, glucagon,
intestinal peptides, catecholamines, cytokines, testosterone, estrogens, etc. [24]. They regulate glucose
splanchnic production [25] and utilization [26–28]. Glucose modulates the production and secretion of
insulin [29] and, indirectly, its hepatic inactivation [30]. However, insulin resistance affects very directly
glucose uptake and metabolism, because of changes in insulin tissue receptors and signaling [31].
On the other side, the 3C fragments (mainly pyruvate, lactate, glycerol) are regulated within the cells,
but not as extensively as is glucose in their inter-organ relationships. 3C substrates, such as lactate or
glycerol can be easily taken up by a wide diversity of cells, even using less specific (or quite different)
transport systems [32,33].
When the cell takes up lactate, it can immediately provide NADH in the cytosol, and then follow
a number of diverse paths to provide C or energy (via conversion to 2C). In comparison, after a
strongly regulated maintenance of its circulating levels, glucose is transported into the cell, converted to
glucose-6P, and then it can be used for the production of 3C (and eventually 2C) through well-regulated
mechanisms. The main potential inconvenient for plasma-carried 3C (specifically lactate) is its charge
(a proton) and its reduced state, which necessarily has to be corrected via production of cytosolic
NADH, but this is the same problem glucose generates at the level of triose-P dehydrogenase. In any
case, glycerol or pyruvate do not comport these hindrances. It is well known that a high number
of tissues use lactate for energy under exercise [34], limited insulin resistance [35], or as a cryptic
“universal cell fuel” [36]. The brain is an active user of lactate [37] and glycerol [38,39]. Liver is a
net lactate user, largely for gluconeogenesis [40,41]. White adipose tissue (WAT) can take up lactate
for lipogenesis [42] or produce it from glucose in large amounts [43,44]. The intestine also provides
3C substrates, in part as a product of digestion [45]. The transfer of energy to tissues via 3C has
been found to be much higher than often considered [46,47], constituting a clear alternative to intact
glucose [47,48]. Under conditions of excess glucose availability, its conversion to 3C eases the pressure
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over the regulation of glycaemia and allows for the direct use of its energy via 3C [48,49], in a way
comparable to the “pre-preparation” of fatty acids (2Cn) fragments to plasma-soluble ketone bodies
(2C2 fragments). The relatively lax control and ease of direct metabolic incorporation allows for a
loosely regulated use of 3C anywhere. This possibility is extensive to the nervous system, which can
use 3C fragments to a large extent as a source of energy in addition to glucose (or as its substitute) [50].
Figure 3 shows the relationship between dietary nutrients and the 2C and 3C substrates pools.
In addition to the carbohydrate paths shown in Figure 2, a large part of amino acid hydrocarbon
skeletons can be incorporated to the 6C→3C pathways (largely glycolysis and gluconeogenesis) but
also as intermediates of the TCA cycle (which eventually will result in OAA and then to a 3C fragment
used for energy or synthesis. Lipids, essentially triacylglycerols (TAG), also provide 3C (as glycerol),
but their carbon is essentially structured in 2C units (acetate, acetyl-CoA) or—massively—in 2Cn
chains, such as fatty acids.
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4. Are There Glucose Specific Requirem nts? The P culiar ties of Erythrocytes and Nervous
System Cells
Glucose (in general terms, hydrate) is required as main dietary macro-comp nent
for ans. [51], also pro ably being an essential component of di t, at least by default [52].
The co mo ness, diverse forms, and igh roporti ns of carbohydrates in many diets has masked
this condition [52]. Nevertheless, the extended use of high-fat and high-protein diets resulting in
inflammatory responses and metabolic alterations [53] points to the requirement of a sufficient amount
of 6C substrates (preferably as 6Cn polysaccharides) in any normal health-sustaining diet, in proportions
of 6Cn not different at present from our early hominid ancestors [54].
The notion that the brain only uses glucose as a substrate remains alive in many texts and studies,
largely for the disproportionate basal consumption of glucose by the brain in comparison with most
other organs [55]. However, the widespread existence of intercellular lactate-glucose micro-cycles
between glia and neurons suggests otherwise [56,57]. The main substrate for brain energy changes
with development [58], but the nervous system continues using a large proportion of blood glucose
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under standard conditions [55], whether this is a consequence of glia cells (i.e., astrocytes) producing
lactate from glucose to feed neurons [59] or the neurons themselves using glucose directly is a question
not yet settled [60,61]. The intensive utilization of lactate and glycerol by the brain as a whole has
been known for more than half a century [38,62] and may be part of a system of protection against the
chemical dangers posed by glucose reactivity.
From the earliest stages of development, the nervous system has specific needs for some nutrients,
such as glucose, as key source of energy [63]; oligosaccharides containing galactose and other sugars [64];
3C fragments, as indicated above; specific essential fatty acids [65]; and enough amino N and essential
amino acids [66]. The needs of peripheral and enteric nervous systems are less known; in the last
case, we have to include the direct relationships with intestinal microbiota [67]. In any case, it is
widely acknowledged that the brain has priority over the rest of the body with respect to glucose
supply [63]. The extent to which the requirements of 6C can be substituted by 3C is yet an object of
discussion [60,61].
The erythrocytes (at least the non-nucleated mammal—including human—ones) are also peculiar
with respect to the need for glucose. They require integer glucose, since they are not able to get
energy via oxidation of 3C. Thus, these cells are considered purely glycolytic, releasing lactate from
glucose [68]. Since the red blood cells need little energy and are a fundamental component of the blood
(which carries glucose), their needs can be easily covered by direct uptake from plasma [69]. Because
their consumption is non-oxidative (6C to 3C), the return of two 3C units per glucose does not alter the
global equation of glucose consumption and do not represent a quantitatively critical factor, as can be
the case with parts of our nervous systems.
5. 2C Substrates, the Critical Conditioning of the Lack of a Glyoxylate Shunt
The triad of TAG, fatty acids, and acetate/acetyl-CoA represents decreasing levels of complexity
of most energy-related lipids; their MW is related directly to their physical conditioning and metabolic
usage. A critical point is their lipophilic nature, which conditions transport by the blood and the
crossing of intracellular and plasma membranes. Acetate (2C) and easily metabolizable ketone bodies
(2C2), as well as some short-chain fatty acids, are hydrophilic enough to be transported in blood or
lymph and may cross easily most membranes [70]. Fatty acids (2Cn, medium to long-chain with
less than five to more than 10 2C units) are transported bound to proteins [71], and are incorporated
into the cell by specific efficient binding-proteins [72] and transporters [73]. TAG are too large and
insoluble to be carried by blood plasma: they are transported within lipoproteins, structured with
apolipoproteins and other lipids, such as phospholipids and other classes of lipophilic compounds as
minority components. The intestine and the liver initially build up these complex lipid carriers, mainly
chylomicra and VLDL. They are fairly efficient systems for transporting large amounts of TAG (i.e.,
heavy energy packages, mostly containing 2Cn) to provide fuel for energy and organ functions [74]
in addition to the transport to and from of critical lipophilic substrates such as cholesterol, a process
reserved for the smaller lipoproteins (LDL, HDL) [75].
Within tissues, large amounts of lipid are transferred between cells by using at least two
mechanisms. In the first, very large (often old) adipocytes, (or those marked for apoptosis), when broken
up via apoptosis or autophagia, release a large amount of micro-drops of lipid. These vesicles are taken
up via pinocytosis by macrophages, functional adipocytes [76], or other cells. A selective apoptotic
(and packed groups of macrophages [77]) process has been proposed as a mechanism for tissue
turnover, which is applied to dead or no longer functional adipocytes [78]. This clearing process has the
advantage to constrain the diffusion of cell debris and lipid drops that can cause damage to other cells,
as well as limiting the clogging of individual macrophages with the remains of apoptosis [79]. The other
mechanism is the use of exosomes or vesicles, which can transfer signals, proteins, nucleic acids,
but also TAG between cells [80,81]. This (incomplete) list represents a wide panoply of mechanisms for
transfer of 2C-based substrates, primarily between the splanchnic bed to peripheral tissues, for storage
or direct utilization.
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The question of transport between cells and tissues is critical for the supply of energy on time,
in the most efficient chemical form for immediate use, and with a sufficient transfer rate of to cover the
needs. This is, probably the main reason why there are two main systems for sending energy substrates
to the tissues via blood: a) lipophilic (2C-derived, energy-dense but large and difficult to handle) and
b) hydrosoluble substrates, represented by glucose and 3C, but also the smaller 2C components soluble
in plasma. The logistic advantages of having both systems rely essentially in the highly dense energy
TAG as substrates sent elsewhere for heavy needs, and a variety of other metabolites, usable directly
by the cells faster to supply in a continuous way, and easily subjected to immediate regulation.
The irreversible path of 3C to 2C is carried out by the pyruvate dehydrogenase complex [23]
(Figure 4), which is highly regulated [82,83] and controls the entry of 3C into the mitochondrion [84].
We can use glucose to build fatty acids, but the reverse (regular fatty acids to glucose) is not possible
because of this critical step at the confluence of the 2C and 3C worlds. This irreversibility is typical of
animals, since plants and other phyla possess the “glyoxylate shunt” that we do not [85]. Probably,
we lost this shunt along evolution because the main source of 2C to feed the TCA cycle and fatty acid
synthesis remained glucose-derived pyruvate.
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The 3C→2C path irreversibility has important consequences for glucose and energy partition:
while 6C→3C and 2Cn→2C relationships are reversible, 3C→2C is unidirectional. In plants, fatty acid
reserves can be converted into 6C [86]. However, in humans and other animals, glucose (or other
convertible 6C) is needed to provide the 3C fragments used in many metabolic paths, since despite the
possible excess of 2C, no 3C derivatives can be obtained from them. This leaves us with an inefficient
system to obtain energy from 6C when converted to 2C, and later oxidized via TCA cycle. An excess of
2C can be corrected only either storing it as fat or through its complete oxidation, whilst any excess of
6C or 3C can be used by a wider range of metabolic pathways, or ultimately derived into 2C.
6. Handling Glucose, Energy Homeostasis, Substrate Cycles, and Distribution
The reversible 6C→3C glycolytic conversion, and the easy entry of 3C in most cells results
in a strategic advantage of distribution, limiting substrate buildups whilst maintaining their full
homeostatic availability. This process is sustained by the existence of substrate cycles within adjoining
groups of cells in a given tissue, as is the case of muscle [87] or the brain, between glia and neurons [56].
The substrate cycles between different organs are widely known, e.g., the Cori cycle [88] or the
glucose-alanine cycle [89], in which exercising muscle converts glucose to 3C, later taken up by the liver,
prompting gluconeogenesis (i.e., 3C→6C) with the overall result (Cori cycle) of transfer of reducing
power from peripheral tissues to the liver [90]. In this case, the 3C→6C interconversion helps transfer
reducing power (or 2-amino groups in the case of alanine) to the liver for their reutilization (Figure 5)
or disposal. This inter-organ coordination prompts a more efficient use of energy and oxygen (and
2-amino N), helping to maintain the levels and availability of substrates.
Most of the inter-organ substrate cycles were described as mechanisms preventing the dangers of
reducing power or 2-amino N accumulation in muscle or other peripheral tissues under conditions of
active use of glucose or amino acids (i.e., during exercise) for energy; they always present a time-delay
component for maximal effectiveness. The exportation of 3C carrying the excess reducing power
or N to the liver has the additional advantage of allowing the return of these 3C to the blood as
glucose, completing a cycle. However, these “cycles” usually work, in real-time, as simple vectors for
transfer—“open interrelationships” (Figure 5), making full use of the differential organ oxygen supply
to transfer a reduced 3C (i.e., lactate) from active muscle to other muscles or the liver to regenerate
glucose, resulting in a chain-transfer of reducing power [91]. This situation can be sustained only when
glucose is not in excess (in the liver), since it may block gluconeogenesis [92], but the excess reducing
power can be easily corrected because of the high liver oxygen supply, removing lactate immediately or
after a delay and even after a buildup of acidosis [93]. The maximal “reduction” of open cycles can be
found in the lung, which scarcely uses glucose [94] but uses blood protons (as the liver do) exported by
relatively hypoxic tissues, using their energy at the mitochondria and thus helping limit acidosis [95].
A special situation is that of adipose tissue; it has been found to generate large amounts of 3C from
glucose [48]. This process has been suggested to help lower glycaemia (and its associated problems)
under conditions of excess substrate availability [96]. The extent of this transformation is considerable,
especially in the mesenteric adipose mass, which receives the mixed 3C-6C results of digestion before
sending them via portal vein to the liver [49]. This peculiarity is not limited to adipocytes, since the
adipose stromal cells act in the same way: a practical anaerobic glycolytic conversion of 6C to 3C
even under full oxygen availability [49]. This may be considered either as another contribution to
regulate glycaemia or as an alternative to produce 3C fragments (essentially lactate and glycerol) in
massive amounts to supply ready-to-use energy to most organs (including the brain) to circumvent
the regulatory difficulties of glucose utilization under situations of excess substrate and/or insulin
resistance [36,43,47,96]. The ample use of 3C as main energy substrate agrees with this interpretation.
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7. Enter the N: Amino Acids, the Question of Diversity of Pathways, and Our Deep Lack of
Knowledge of Them
Curiously, and despite their primeval importance, amino acids seldom are considered
quantitatively important substrates for humans in analyses of overall energy metabolism. The most
used explanations for this ellipsis are:
• The often incomplete hydrolysis of dietary proteins [97];
• Intervention of microbiota through transformation/catabolism or even synthesis of amino acids [98];
• Further transformation/catabolism by the intestine and the liver before overall distribution [99];
• Sparsely known real catabolic pathways for many amino acids [100–103] in humans;
• The absence of specific amino acid/protein reserves;
• The lack of knowledge on the regulation of essential amino acids;
• The gross differences between measured calorimetric pump energy content of proteins and the
real energy obtained in vivo from amino acids according to the known (or assumed) metabolic
pathways [103];
• The assumed relatively small amount of actually oxidized amino acids derived from the diet
compared with carbohydrates and lipids;
• The uncertainty on how the N of amino acids is processed and excreted [104], which directly
affects the estimations of dietary amino acid use [105];
• The “diversity and complexity” of amino acid catabolism;
• The common absence of data on diet protein amino acid composition.
In fact, the main question for eluding amino acids from most studies is the lack of knowledge.
We do not know yet (in humans) the complete catabolic pathway of several essential amino acids or the
implication and compartmentation of the catabolism of amino acids yielding 1C, 2C, 3C, and 4C/5C
intermediates of the TCA cycle. To complicate further the analysis, we have only an approximate
knowledge on how the dietary protein (in fact, the amino acids resulting from their digestion if
assimilated) translates into metabolizable energy.
The role of a few amino acids in the maintenance of glycaemia via gluconeogenesis [89,106] is
well known, but the focus is now on branched-chain amino acids [107,108]. These amino acids are
catabolized to 2C fragments (leucine and isoleucine) and propionate (valine and isoleucine) [109] (nor
a 3C but an important anaplerotic precursor of 4C fragments [110]). Some amino acids (such as alanine
or serine), when oxidized, i.e., after their amino moiety has been removed, yield directly 3C (pyruvate).
Others (i.e., leucine, lysine) are mainly broken down to 2C, but most are oxidized to intermediate
metabolites of the TCA cycle (e.g., glutamate, aspartate, threonine). A simplified scheme of the fate of
hydrocarbon moiety of amino acids is shown in Figure 6.
The amino acid hydrocarbon skeletons can, thus, provide 2C or (in a higher overall proportion)
3C, but also the high-energy containing 4C and 5C fragments, which, eventually will be converted
into 3C along the TCA cycle, hence their importance for gluconeogenesis under conditions of severe
energy stress. However, the use of 2C for 2-ketoacid synthesis is almost nil, widening the 2C-3C
chasm. In fact, the variation of amino acid catabolic pathways results in a simplified handling of
their complexity—losing in some cases energetic efficiency in the process—for gross energy purposes
(as shown in Figure 6) than usually believed. As to the aspects of regulation cited above, we are yet in
a serious state of ignorance, with few exceptions.
Int. J. Mol. Sci. 2020, 21, 7729 11 of 38
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 11 of 39 
 
the implication and compartmentation of the catabolism of amino acids yielding 1C, 2C, 3C, and 
4C/5C intermediates of the TCA cycle. To complicate further the analysis, we have only an 
approximate knowledge on how the dietary protein (in fact, the amino acids resulting from their 
digestion if assimilated) translates into metabolizable energy. 
The role of a few amino acids in the maintenance of glycaemia via gluconeogenesis [89,106] is 
well known, but the focus is now on branched-chain amino acids [107,108]. These amino acids are 
catabolized to 2C fragments (leucine and isoleucine) and propionate (valine and isoleucine) [109] (nor 
a 3C but an important anaplerotic precursor of 4C fragments [110]). Some amino acids (such as 
alanine or serine), when oxidized, i.e., after their amino moiety has been removed, yield directly 3C 
(pyruvate). Others (i.e., leucine, lysine) are mainly broken down to 2C, but most are oxidized to 
intermediate metabolites of the TCA cycle (e.g., glutamate, aspartate, threonine). A simplified scheme 
of the fate of hydrocarbon moiety of amino acids is shown in Figure 6. 
 
Figure 6. Summary of the final conversion of dietary protein amino acids in 1C, 2C, 3C, 4C, and 5C 
fragments, which revert essentially into 3C and 2C, during the human catabolism of amino acid 
hydrocarbon-skeletons. The pathways used to prepare this graph are the most common, including 
the main alternate pathways [105]. The green lines show the carbon paths for each amino acid, the 
brown lines represent the relationship between the core of the TCA cycle and pyruvate 
dehydrogenase (with the loss of one CO2 between each substrate group box (marked in yellow). Non-
standard abbreviations: Hyp = L-4-hydroxyproline; Orn = ornithine; “1C” = One-carbon fragment 
donor systems. 
The amino acid hydrocarbon skeletons can, thus, provide 2C or (in a higher overall proportion) 
3C, but also the high-energy containing 4C and 5C fragments, which, eventually will be converted 
into 3C along the TCA cycle, hence their importance for gluconeogenesis under conditions of severe 
energy stress. However, the use of 2C for 2-ketoacid synthesis is almost nil, widening the 2C-3C 
chasm. In fact, the variation of amino acid catabolic pathways results in a simplified handling of their 
complexity—losing in some cases energetic efficiency in the process—for gross energy purposes (as 
shown in Figure 6) than usually believed. As to the aspects of regulation cited above, we are yet in a 
serious state of ignorance, with few exceptions. 
Figure 6. Sum ary of the final conversion of ietary protein amino acids in 1C, 2C, 3C, 4C, and 5C
fragments, which revert essentiall i t , uring the human c tabolism of amino acid
hydrocarbon-skel tons. The pathways used to prepare this graph are the most com on, including the
main altern te pathways [105]. The gre n lines show the carbon paths for each amino acid, the brown
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8. The Dangerous Duality of Needed 2-Amino-Nitrogen Preservation and Its Ill-Understood
Disposal Pathways
From an evolutionary point of view, our design evolved to preserve 2-amino N, since we cannot
significantly use other sources of 2-amino N than amino acids themselves (obtained from dietary
protein). All amino acids are synthesized by plants (and other phyla) and used to build their own
proteins. We use (eat and digest) these same proteins to obtain the amino acids we need to form our
self-proteins and other N-containing molecules (e.g., purines, pyrimidines, porphyrins, etc.). All our
amino acids have been obtained (from the diet) either preformed—e.g., essential amino acids—or
rebuilt by us from available hydrocarbon structures and 2-amino N suppliers, i.e., amino acids from
plant or animal (formerly “plant”) sources. Since we are omnivores, the dietary protein is just another
source of energy, used, for this purpose, in proportions that depend on their availability [111,112].
Thus, the complex safety measures established to retain amino acid N necessarily should interfere
with their utilization for energy. Nevertheless, it is obvious that essential amino acids are continuously
oxidized for energy irrespective of their source: if there are not changes in body protein (in addition to
the “obligatory” protein losses: Box 1), the amount of these amino acids ingested in the diet should
tally their oxidation, since they cannot be stored.
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Box 1. Forms of excretion/loss of nitrogen in humans.
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The main, basic studies on our ha li of diet amino acids, protei synthesis, and recycling
of amino N were e sentially more than half century ago, and they were invariably focused
on the ways to pres rve N, the mechanisms to s rvive u der conditions f starvation [113], dietary
protein deprivation [114] and, globally, malnutrition [115,116]. Amino acids as energy staple have
been, since, considered “secondary” (or at most “complementary”), and their assumedly “complex”
metabolism was oversimplified around their possible use as gluconeogenic substrate under glucose
deficits or generators of ketones (ketogenic) during starvation [117]. The epidemic nature of obesity,
developed thereafter, and the need to find ways to cope with its ravages were centered on glucose and
fats, a situation that continues with limited global interest on amino acids as energy substrates under
conditions of plenty [118,119]. The key problems that remain and prevent further advances in this
direction are the diversity of metabolic pathways used to oxidize the hydrocarbon skeletons of amino
acids, the relatively unknown mechanisms to retain essential amino acids, and, especially, the not yet
clarified variable fate of the N moiety of amino acids during their catabolism.
The canonic mechanism of excretion of the N moiety waste is the urea (or Krebs–Henseleit)
cycle [120] (the “first” Krebs’ cycle [121]), a very peculiar pathway between cytosol and mitochondria.
It may also harbor a shunt to generate nitric oxide (NO·) and citrulline from arginine [122]. The daily
losses of N via the NO· pathway are a fraction of the overall N excretion, essentially made up
from nitrogen oxides released through respiration [123] (a few µg/day) or further oxidized to
nitrite, nitrate, and other nitroxylated compounds [124,125], which are excreted via saliva, urine,
and stool [126,127]. However, there is proof of an additional, quantitatively significant, excretion of N
as gas through respiration [128,129] that is supplementary to the standard and well-controlled urea
excretion. When analyzing in detail N balances in experimental animals, the amount of N ingested
is higher than the sum of the N accrued in the body and the N excreted and accounted for [130,131]
(Box 1). The proportion of this “nitrogen gap” (assumedly N2) is in the range of 5–15% of all nitrogen
ingested and not accrued (i.e., it is actually excreted), and its amount is related to diet and energy
status [128,130]. It has been found that this N2 loss is related to arginine metabolism [131] (Figure 7).
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Figure 7. The nitrogen “gap: in rats. A “nitrogen gap” was found when analyzing all the components
of the nitrogen balance in young rats: i.e., the N ingested, that excreted by urine and feces as well as the
total N accrued, thus proving the existence of a sizeable part of the N excreted not as urea, or through
the other possible ways and means shown in Box 1. Different complete (measuring both sides of the N
balance equation) studies repeated these findings, dependent on diet, and with a magnitude (in rodents
at least) in the range of 10–30% of all nitrogen excreted. Redrawn with data from Esteve et al. [130].
In fresh-water plants [132] or fish [133,134] living under high (cytotoxic) ammonia concentrations,
the levels of NO· are high, and the production of NO· is increased several fold on exposure to ammonia,
assumedly potentiating its oxidation [134]. The most suggestive process is that of the anammox
(anaerobic ammonia oxidation) bacteria [135], which assumedly use NOx, probably via NO· to oxidize
NH4+ coupled to the reduction of NO· [136].
Both ammonia and nitrite or nitric oxide can react spontaneously in an exothermic reaction,
yielding N2 and water [137], provided that ammonia is protonated to ammonium and the extra
electrons are removed
4 NO + 2 NH4+→ 4 H2O + 3 N2 + 2 e- (1)
This is a reaction very similar to the integral oxidation of ammonia with nitrite [138],
NO2- + NH4+→ N2 + 2 H2O (2)
which can be reproduced very easily in the laboratory with minimal means. N2 is also produced by
the reaction of nitrite with amino acids at low pH [139]. The abundance of nitrite produced in the
inactivation of NO· could justify a small part of the production of N2, in part via its reaction with
amino acids [140]. However, this process has been studied under conditions seldom found in a living
human [139]. Nitrite may react more easily with ammonia, but their low circulating levels [141],
and the small area of diffusion of newly-created NO·, in the µm range, may prevent this reaction
taking place, except, perhaps, in the gut lumen, where the levels of ammonium and NO· (but not
the environmental conditions) may be higher [142,143]. However, the fact that in axenic rodents the
excretion of N2 is unchanged [128] hint at the existence of a less “occasional” and regulated source for
the production of N2.
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The mechanism of nitrogen gas synthesis from ammonia used by anammox bacteria suggests a
possible pathway in which this oxidation is carried out in two steps [137]:
NO·+ NH4 + 2 H+ + 3 e-→ N2H4 + H2O (3)
N2H4→ N2 + 4 H+ + 4 e- (4)
Evidently, the hypothesis we presented in Figure 8 with respect to the postulated origin of N2
from the mitochondrial reaction of ammonia and NO· has a serious weak point, since, as far as we
know, the enzymes that allow the oxidation of ammonia by NO· (under anaerobiosis) are exclusive of
anammox bacteria. However, the possibility of hydrazine being an intermediate step in the process
could not be fully discarded given its limited toxicity (it has been used for the treatment of tuberculosis
and cancer [144]) and its widespread effects on amino acid metabolism [145].
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Figure 8. Hypothesis for the origin of a onia and nitric-oxide generation of nitrogen gas in
mitochondria. The coexistence in the liver mitochondrial matrix of both ammonia/ammonium and
nitric oxide, within well-regulated pathways, in significant amounts, and related to the urea cycle,
suggests the possibility of a reaction which may generate nitrogen gas at the expense of both. This is a
speculative hypothesis, which has not been proven so far. In any case it is difficult to justify the presence
of both reactants in a relatively high concentration without interacting, since the uncontrolled chemical
reaction between them is spontaneous and exergonic. In this hypothesis, we include the findings of
Kartal et al. [137] in their study of the mechanism of ammonia oxidation in anammox bacteria, which
has an intermediate metabolite between them, hydrazine (N2H4). The two enzyme activities of the
complex hydrazine synthase and hydrazine dehydrogenase are intimately related to membrane of the
anammoxosome particle.
Ammonia and nitric oxide are both produced in significant amounts in the mitochondria:
ammonia through—mainly—glutamate dehydrogenase [146] and glutaminase [147], and NO· via NO·
synthase [148] (Figure 8). One can speculate that within the mitochondria, the reaction 1 can take
place through a regulated mechanism. The main problems for this hypothesis to be confirmed are
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the so far unidentified catalyzer system, and the question of the low solubility of N2 in biological
fluids but not on fat tissue, several-fold higher than in plasma [149,150], to carry the gas away to
be exhaled in respiration. This type of shunt is, probably, the base for the known excretion of N2
gas under certain circumstances (high arginine, high protein) resulting also in excess ammonium in
the mitochondria [151]. This uncharted metabolic path is affected by diet, sex, and excess energy
and amino-N availability [128,130,131], and constitutes an example of our extremely low level of
knowledge on the mechanisms and factors that govern substrate energy partition. This uncertainty
affects seriously any quantitative study on this subject.
9. Reserves, a Highly Reserved View
We need (and thus maintain) reserves of all possibly scarce materials we need: essential metals,
ions, sulfur, selenium, some vitamins, and especially 2-amino-N. Evidently, we also store energy.
The balance between reserves, their type and the problem of carrying them as part of our body weight
has been extensively studied, but often, we tend to maintain excessive long-term reserves of lipid
(2Cn). We retain a lower amount of 6Cn reserves (glycogen) for hypoglycemic emergences, and we also
keep a small supply of phosphagens for immediate support to the first line of response (ATP).
Metabolic syndrome (MS) and similar conditions related to excess of energy supply create havoc
with the management of reserves, since the unmanageable excess of 2C tends to end as lipid, which
is massively stored for lack of alternatives. This problem derives largely from our taste for fat [152]
(inherited from our ancestors because of its high energy density), perhaps helped by our ingrained
memories of lactation [153] and the availability of “tasty” lipid-rich foods [154]; but it is also derived
from an unbalanced supply of energy (especially in excess) of 2C vs. 3C as a main energy staple [155].
Our main (from a quantitative energy content point of view) physiological reserves are made
of fat because WAT contains up to 80% TAG (in the range of 30 MJ/kg) [156]; thus, a few kg of WAT
may provide enough energy for our basic sustenance for months (Table 1). Its main advantage is
the high energy densities of fat and the adipose tissue holding it, especially when compared with
polysaccharides. Our reserves of glycogen are small [157] and were devised to sustain glycaemia for a
short time, since glycogen contains about half the energy than fat (on a dry weight comparison basis).
In addition, it is highly hydrophilic and retains a large amount of water (added weight, limiting its
accumulation in significant amounts) [158]. A high weight (including water) with respect to energy
content limits movement excessively in exchange for short-lived reserves; thus, the main reserves,
the more effective in terms of energy/weight are lipids. However, their real effectiveness depends on
the body mass of protein [159].
Table 1. Mass of energy reserves in the human body.
A—Main body reserves mass and its energy equivalents in adult healthy humans.
Group
Reserve Primary Final Catabolite
Type Mass, kg Available, kg Energy, MJ MJ 2C MJ 3C 2C/3CRatio
women body protein 10.6 2.1 36 4 32
men 13.5 2.7 45 5 41
women liver & muscle
glycogen
0.38 0.37 6.4 0 6
men 0.48 0.47 8.2 0 8
women body fat 12.7 12 445 418 27
men 16.1 15.3 561 527 34
women
totals
487 422 65 6.5
men 614 532 83 6.4
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Table 1. Cont.
B—Whole-body plasma metabolite and energy content equivalents of adult healthy men †.
Energy
Metabolites
mM Whole Plasma mmol
Primary Final Catabolite
mmol 2C mmol 3C 2C/3CRatio
proteins * 660 170 17 153
triacylglycerols 1 2.6 25 1
glucose 5 13 0 26
amino acids 4.5 11.7 1 11
glycerol 0.05 0.1 0 0.1
lactate 0.15 0.4 0 0.4
NEFA 0.4 1 9 0
totals 52 192 0.27
† No data have been presented for women, because the scant gender differences in the levels of metabolites, and any
correction for plasma volume would not give different values for the final 2C/3C ratio. * Molarity of proteins
is expressed as mmol of amino acid residues (mean MW of 105 in the present calculations) [160]. The data in
the A part of the Table were taken from Frayn [161], modified with results of [162] and including unpublished
data in the calculations. We used standard body weights for men (70 kg) and women (55 kg) to homogenize the
data. We assumed that from the whole body protein, only about 20% may be used (allowing recovery) under
starvation to cover the body’s energy needs. This datum was calculated from a study of long-term food deprivation
in rats [163]. Similarly, an arbitrary limit of 5% minimum of body fat (i.e., not available for energy mobilization)
was introduced in the calculations for lack of direct references. No information has been added with respect to
more “immediate: energy reserves, such as phosphagens (e.g., creatine-P) and ATP because of their low global
energy entity in comparison with the three main storage pools described here. The data in the part B of the Table
were calculated only for plasma (i.e., estimated from blood volume minus blood cells, using normal standard
concentrations, and a hematocrit value of 43. Here, instead of referring the substrates to their energy content,
we used molar concentrations, since they were the primary data.
The main theoretical problems posed by body fat reserves are essentially two: a) its use as storage
of energy may derive into being a 2C dump when energy intake is excessive, driving to obesity,
inflammation and MS [164]; and b) we need, specifically, glucose/3C for inter-organ supply of energy.
Thus, sources of 3C should be taped to preserve our homeostasis under conditions of severe scarcity;
even when there is a large excess of 2C reserves available, we keep needing a steady supply of 3C,
which often requires the sacrifice of protein [165]. In practical terms, the main 3C “reserve” of the body
are the proteins (irrespective of their functionality). However, since we do not have protein reserves as
such, we have had to rely on misadjusting the overall turnover rates to degrade faster and synthesize
less protein [166], draining the amino acids freed to generate 3C, especially during starvation [167].
The data shown in Table 1 are only general approximations, but the figures of storage substrates
and circulating compounds used with different intensity as nutrients throughout the whole body
illustrate clearly the enormous difference between the make-up of 2C substrates and the 3C ones that
may be used for functions other than the generation of energy through the TCA cycle. The 2C/3C
ratio for all added-up energy reserves in normal weight healthy adults is about 24-fold higher when
considering body reserves than when we analyze the nutrients carried by blood plasma. This highlights
the differences (even with all logical caveats considered) between what is the homeostatic internal
medium composition, akin to our immediate substrate supply needs, and what we have retained.
The weight of 2C is overwhelming.
In Table 2, we have intended to obtain a value of the C2/C3 ratio in the human diet. The problem is
the absence of data (especially on protein composition of the enormous varieties of diets) We analyzed
the C2/C3 ratio for a “theoretical” adult healthy human eating a standard diet, such as those being
recommended for a “healthy nutrition” by most specialists. The results were again shocking: the
final ratio of the standard diet was in the range of 1/5th of that of our “normal” body composition,
and it was more than five times higher than the plasma nutrient ratio. These differences stress an
innate deficit of 3C yielding substrates, necessary to maintain energy homeostasis with respect to
the energy stores, strongly decanted toward the 2C supply, making a large part of these reserves not
physiologically usable and, in fact, only “dead weight”. This unchecked domination of 2C sources hint
that our standard diets are probably inadequate, chosen more because of factors different from the best
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metabolic adequacy (taste, availability, social or historical factors, etc.). The recommendation of such
types of diet adds to the problem they pose, since recommendations are based on population statistics
with no ‘controls’ to refer to. They are not based on sound biochemical metabolic comparative data,
simply because they have not been (sufficiently) investigated. The consequences are crystal-clear:
a growing pandemic of diet-borne disorders, essentially undiagnosed, not treatable and affecting a
large (and growing) proportion of our Society.
Table 2. Estimation of the 2C/3C relationships of a human standard diet.
Macronutrient Food Intake, g
Energy Intake Primary Final Catabolite (mmol/d) 2C/3C
Ratio% kJ/d 1C 2C 3C 4C + 5C
carbohydrate 345 55 5775 3830
lipid 84 30 3150 5400 100
protein 94 15 1575 59 413 93 406
totals
100 10,500 59 5813 4023 406 1.44
5813 4429 1.31
We used standard consensus-recommended diet compositions [168,169] adapted for a 70 kg healthy adult man,
assuming his body weight remains without changes (goals expressed by the WHO and EFSA in the references cited
above), that is with no accrual neither losses. The intake was adjusted to 10.5 MJ/d (2500 kcal/d or 122 W). Obviously,
the distribution in final metabolites for protein may be subjected to wider changes than lipids and carbohydrate,
depending on the protein sources of the diet. We have not found published data for population-wide analysis of
amino acids for diet protein composition related to complete and time-sustained normal human diets. In order to
get an approximation to the sought data, we used instead data for rat cafeteria diet of previous studies from our
research group [170,171], on the assumption that the “cafeteria” diet was devised to mimic the usual consumption
of food of young humans late in the past century in urban Westernized settings [154]. In the rat cafeteria diet used,
the amino acid residues had a mean MW of 126.
It is important to add an additional commentary on the methodology we use at present with
diet (food) analyses. Despite the considerable difficulties, assumptions and techniques available,
the classical study of Atwater [172] remains the “current” basis for our energy intake/expenditure
calculations. In 12 decades, science has changed considerably, and precision is one of the critical points
for accepting such widely used data. A recent critical analysis of the methodology used by Atwater
but applying present-day criteria [173] showed that a significant deviation of the original data exists,
and that we urgently need methodology more adapted to today’s conditions.
The dynamic situation of lipid reserves is clear and understandable. What is not is the reason
why some body fat seems impossible to mobilize even using very-low energy diets [174,175] even with
metabolic situations close to starvation, which resulted in scant (if any) mobilization of part of the fat
reserves [176], often in spite of real body weight losses (water, protein, minerals). The extra weight and
the inflammation accompanying the excess of adipose tissue fat are severely detrimental for the health
and normal energy handling, and are maintained without any apparent reason [177].
Our energy metabolism overall can sustain, in a large proportion, the substitution (as energy
substrates) of part of carbohydrate (3C-givers) by lipid (2C-providers). Carbohydrate may be
compensated in part by protein [178]. However, the N moiety of protein and some amino acids
could not be substituted (but we can lower our needs by modulating turnover rates) [179]. These
compensations include the use of internal reserves (mainly lipid) but also, in part, the lowering of the
body protein pool [165]. These measures do follow well-established priorities in the use of energy
substrates (or, in the end, any substrate) ingested, and, when insufficient, compensated with the use of
reserves [180]. The order of precedence in consumption (that of preservation is just the reverse) [180]
is essentially:
1 Lipid (2C)→2 Carbohydrate (3C)→3 Protein (amino N)
Diet takes precedence in their use for energy over reserves, but changes in the diet may modify
some of these evolutionary rules of precedence, thus protein is needed for lipid oxidation and to
prevent its storage [181]. These mechanisms were developed, and refined with efficient regulatory
mechanisms, to enhance survival by maintaining energy homeostasis under conditions of insufficient
Int. J. Mol. Sci. 2020, 21, 7729 18 of 38
food availability (including starvation), and incorporating the hypothesis of thrifty genes and their
possible incidence in the development of diabetes/obesity [182,183]. However, we have not established
a metabolic process (spendthrift) to cope with a simultaneous excess of energy and of all main nutrient
classes in the diet. No process has evolved to solve this situation because this is a peculiarity, affecting
practically only our species, which appeared in a very short time (in evolution terms) [183]. The trend
is fueled in part by the setting of epigenetic traits favoring the development of obesity, despite its real
deleterious effects [184,185]. We have no historical evolutionary memory on how the problem of excess
can be handled, since our tools are useful only to counter scarcity, and thus, the mechanisms/processes
applied are often not only inadequate, but self-defeating and harmful.
10. The Triad of Main Energy Sources and How Sorting of Substrates Seems to Proceed
We ingest food for energy and growth/maintenance. Evidently, a large part of the main substrates
(amino acids, fatty acids, sugars and intermediate metabolites, as well as most essential components)
are used in connection with turnover strategies of our own living matter, in order to maintain all
mechanisms in their prime efficiency. However, from a theoretical (quantitative) point of view, intake
should match excretion and energy loss (assuming that there is no real change in our mass) [186,187].
Thus, the main types of substrate we ingest for energy (with all provisos stated above) belong to three
groups: amino acids (N providers), 3C and 2C providers. After a large portion of amino acids is sieved
and selected, they revert largely to “excess N” plus 2C, 3C and 4C (TCA cycle intermediates) (Figures 2,
3 and 6). The final proportion of 2C and 3C available during a certain stretch of time depends on
digestion, rhythms etc., but we can just center the question in basic one-day periods. Under no-growth
conditions (i.e., no additional storage of energy: only turnover) almost all 2C will end as a source
of energy via TCA cycle. 3C have a higher variability of uses, but at last, all excess 3C is converted
to 2C, which is then oxidized for energy (or stored as fat). If there is a large excess of amino acids,
the elimination of N stresses the 2C/3C setup, both because of anaplerotic enhancement of TCA cycle
(via 4C) and an intense pressure for growth, which increases protein synthesis and “storage” as body
protein. Most of these effects/mechanisms remain rather unknown, because almost never come alone,
and are largely mediated via gene expression and hormonal modulation affecting select different
groups of cells.
A large part of nutrients is used with little change (if any) for turnover (e.g., amino acids, fatty
acids, glucose, etc. for, respectively, proteins, TAG or glycogen), or to build-up reserves (i.e., fatty
acids) or (almost all compounds) for growth and reposition of live matter lost (i.e., hair, epithelial
cells or secretions). Amino acids could not be substituted from the point of view of reposition and
turnover, as well as for the synthesis of other N-containing body components. Carbohydrates may be
substituted, largely, by protein, but the loss of energy in the complex catabolism of some amino acids,
plus the need to dispose-of 2-amino N markedly limits the extent of this substitution. On the other
side, lipids (e.g., TAG, but not including the essential fatty acids) can be entirely substituted because
their sole specific metabolic contribution is to provide large amounts of 2C, which we are prepared to
compensate with protein and, essentially carbohydrate.
An excess of 2C, on the other side, limits the utilization of dietary fatty acids, which are then
incorporated to the stored fat reserves, without previous oxidation to 2C [188]. This is an efficient way to
store dietary energy, quite different from the energetically expensive lipogenesis from acetyl-CoA [189].
This 2C molecule is also in excess (limited by the availability of coenzyme A because of insufficient
capacity of the TCA cycle to oxidize it, since reducing power/ATP are produced on demand. This is
compounded by limited lipogenesis, restrained because of the excess of dietary fatty acids [190].
The large acetyl-CoA availability, due to its limited need, inhibits the oxidative decarboxylation of
pyruvate, the critical 3C→2C unidirectional process [191], thus secondarily provoking an unwanted
accumulation of 3C. In parallel, glycolysis is also limited because of insufficient 3C removal [192],
which results in lower glycolytic processing of 6C, which adds to the excess carbohydrate provided by
the diet together with the unneeded excesses of dietary amino-N and fatty acids (Figure 9).
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Figure 9. Partition-related substitution of nutrients in the diet to fuel th metabolic processes. This graph
intends to explain the absence of a total/complete substitution capability between the three main groups
of nutrients: Protein, carbohydrate and fat, which constitute most of our diet, a least from an energy
point of vi w. Solid lines show the direct relati nship between the grou s of substrat s. The large
red line emanating from 2C represents the oxidation of acetyl-CoA in the TCA cycle to obtain most
of the energy we use. The thinner red dash-lines indicate other main sources of cell ATP, adding up
to the sum of energy available to cover our needs. Part of our food is made up of other components
(minerals, organic micro-components, fiber, etc.). Their relationships with other compounds are marked
with purple lines. SOBC stands for: “synthesis of other body components” from the building blocks
provided by the four groups of nutrients analyzed. Their mixed paths have been marked in black.
The lines in blue represent the metabolism of carbohydrates, including the part shared with amino
acids and lipid. Protein-amino acid paths are marked in green. The lines in dark yellow represent the
paths exclusive of lipids.
The serious difficulty lies on the iterative nature of the process along time. A few days of
excesses can be modulated in part by decreasing appetite and voluntary intake [193], increasing protein
turnover [194], thermogenesis [195] and topping the reserves of glycogen and fat [196]. Nevertheless,
these ‘solutions’ work only to a certain degree, not in a permanent way, and create a regulatory havoc
that cannot be sustained indefinitely. The emergency measures only patch, do not solve the problem,
it is just metabolic procrastination, and in short time deep problems begin to develop [197]; and shortly
afterward, they also become chronic [198,199]. The excesses of substrates could not be disposed of,
and the regular mechanisms of partition cannot function in a fluid way. Obviously, oxidation of 2C is
enhanced, but what to do with the unused ATP? In a global setting, thermogenesis helps, but not at
the level of each cell (largely those in the splanchnic bed). Then, the priorities list ingrained in our
metabolic control systems retake their place of reference.
• Save as many amino N as possible and take special actions to prevent the toxicity of NH3, perhaps
via the alternative “NH3 + NO·” production of N2.
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• Limit the processing of fatty acids to 2C fragments and thus dump them as TAG (with a token
3C glycerol) [200]. This process induces obesity [201], steatosis [202], and drives muscle to be
essentially a fat-infiltrated 2C energy user, with glucose intolerance [203,204].
• The toxicity of glucose (the same occurs with the excess of ammonia) represents an immediate
danger that cannot be “stored” (as are the fatty acids in TAG).
The insulin basic controlling mechanisms of glycaemia no longer function properly [205], in fact
they interfere, limiting the peripheral utilization of glucose as substrate [206,207]. Hyperglycemia is a
problem [208] which is in part corrected by the conjunctive tissue (including adipose tissue), which
actively takes up glucose and returns 3C to the blood [96]. Most tissues may work (including the brain)
perfectly using 3C (largely lactate and glycerol) [36–38,91]. Thus, the blockage of liver metabolism,
in its ↑2C-↑3C no-win situation, is in part corrected by an adipose tissue (also inflamed, engrossed
by the excess lipid storage [209]) which generates large amounts of 3C at the expense of glucose [96].
It also produces urea cycle intermediates, probably to compensate in part for the decreased capacity of
the liver [210,211].
11. Normalization and Regulation under Excess (if Any)
Return to normalcy from the excess-driven picture of energy metabolism is difficult. The search for
drugs is not a viable solution, because the problems observed have a known origin, and the severity of
the damages is largely a consequence of the mechanisms established to ensure survival under scarcity.
We cannot fight these mechanisms because a) we do not know them enough, b) we need them to sustain
our “normal” homeostasis, and c) they have to be operative to achieve that normalcy. Right now,
the main systems in use to fight obesity are—essentially, and despite their limited effect—diet and
exercise; but, what type of diet? Hypocaloric?
Under starvation, the stored fat is progressively shed to last as much as feasible; our bodies adapt
to lower energy, lower carbohydrate and limited protein intake diets, including the absence of fats,
following the blueprints for starvation [212]. The elimination of dietary carbohydrates [213,214] and
lowering of energy intake share some characteristics, because of our adaptability to starvation, but there
is a considerable discussion on the proposed benefits of ketogenic diets, which, in any case, could
not be generalized from epilepsy to obesity [215–217]. Nevertheless, even after prolonged starvation
or removal of dietary carbohydrates, a significant portion of body fat remains, even after prolonged
exposure. Unfortunately, in the practice and for most obese people, dietary treatments remain not
effective [218].
Exercise is an alternative to increase energy expenditure with (or even without) restricted
intake [219,220]. This approach is not always feasible, since obesity is syndromic with cardiovascular
disease and problems of mobility [221] and, despite numerous claims on the contrary, exercise it
not sufficient to revert the damages of an established MS [222], and may not improve the health
status [223]. However, well dosed exercise may provide benefits to mild cases and young patients [224].
In addition, the effectiveness of exercise is also limited from the point of view of energy: limited
duration, limited proportion of increase in overall energy consumed, consequences in the availability
and transport of oxygen and products of substrate oxidation. In fact, exercise is better suited to maintain
functionality [225] (when applicable) than to fight obesity. The chronicity of the “excess situation”
described above, usually continue even when the dietary excesses cease. Too often, very low-energy
dieting and exercise combined (even using additional anti-obesity approaches) are unable to eliminate
the excess fat and reverse the damages already induced by (or accompanying) this excess deposition.
The size of fat depots is a critical point for the severity of the disorders and a barrier to a progressive
and effective removal, often leaving only the alternative of surgical modification of nutrient intake [226].
However, none of these procedures can revert the metabolic homeostasis to the situation prior to
depot engrossment. Nevertheless, drastic treatments may extend the patient life span, improve
the lifestyle and ameliorate a few components of the MS [227,228], but not cure it or its associated
pathologies. The corollary to this exposition is our extreme resilience to change in the energy (and
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nutrient) equilibrium, which allows us to cope with the situation for a time and then alter, in a probably
irreversible (and unknown) way, the common mechanisms for nutrient partition in a situation far
from normal, which could not be sustained indefinitely. However, these changes allow a number of
affected individuals to keep living despite the severe damages to metabolic processes and their control.
A deeper layer of thought (and thorough research) are needed to understand how people can survive
decades under MS conditions.
Probably, excess body fat is directly related to the severity of the disorder it causes: it is commonly
accepted that the body mass index vs. mortality curves are U shaped [229]. However, this index is not a
real indexed measurement of the body fat content, and parallel studies analyzing body fat vs. mortality
showed a lineal direct relationship [230]. Nevertheless, a certain degree of obesity helps protect the
patient from some cardiovascular diseases [231]. The discussion about the causes of the obesity paradox
or even its existence continue, but part of the problem may lie on the inadequate use of body mass
index to “measure” obesity [232], and the question of whether obesity is by itself a disease (or simply a
part of a more severe disorder such as MS). The repeated references to “healthy obesity” (i.e., large body
fat stores without the associated metabolic disorders of “proper” obesity) [233], have been relatively
circumscribed by introducing factors such as age and gender [234]. Our group has postulated that a
certain degree of obesity may help limit the ravages of type 2 diabetes by removing excess glucose
and releasing 3C, being more a (palliative) consequence than a cause for this disease [49,96]. In any
case, the question is not settled, and perhaps there is also a margin for optimal (and not rigidly low,
invariable and universal) mass of body fat reserves other than the one used at present.
Under conditions of excess energy intake, the metabolic handling of substrates is parallel to
modifications in the hormonal mechanisms that regulate energy metabolism [235], since the main
system of regulation of glycaemia (insulin) has been severely damaged [236]. The other mechanisms
complementary to insulin have a wider array of functions: the glucocorticoids, favor liver glucose
output under conditions of stress or metabolic distress [237]. Glucocorticoids also affect the fate of the
main gluconeogenic precursors, amino acids, and altering the excretion of N [238,239]. Testosterone
pairs with insulin as a main anabolic hormone [240], but glucocorticoids tend to limit testosterone
production and availability [241], also affecting the availability of estrogen [242], which plays a critical
function favoring the oxidation of 2C (i.e., saving 3C) in females [243] via direct intervention in
mitochondrial function [244,245], and also preventing liver steatosis [246]. An estrogen-derivative has
been found to down-modulate the adjustment of the ponderostat, i.e., the oxidation/mobilization of
lipids from adipose tissue [247,248], by decreasing food intake and maintaining thermogenesis [249].
Unfortunately, there is insufficient mechanistic information on the effect of estrogen derivatives because
only recently these hormones are considered important metabolic regulators [250,251] and act not only
in the sex-related way indicated by its etymology.
Substitutive testosterone treatment normalizes the glycaemia of mature and old men, a situation
that is slowly being accepted by endocrinologists (diabetologists, in fact) [252,253] after being a mainstay
of the treatment of MS aging-related disorders by gerontologists [254]. Its soothing effect on the MS
ravages [255] is complemented by the already known effects of estrogen on energy partition [256,257],
limiting the storage of lipids. Most of present-day studies on obesity (and of MS, as an afterthought)
are focused on cytokine and regulatory circulating RNA types [258] and the paths they modulate,
which add considerable knowledge on the possible regulation of their mechanisms of action, but not
on the causes/mechanisms of the disorders or the ways to prevent and treat them. Figure 10 shows a
simplified scheme of the main hormone-controlled mechanisms regulating glycaemia.
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12. Diet, Its Composition, and the Central Role of Glucose
Man’s main energy staple has been, in the last millions of years, of plant origin: seeds, starchy roots
or other plant energy reserves, fruits, leafy foods, complemented with some products of animal origin.
Humans have evolved in parallel to their nutrition [265]. Foods from animals have been increasing
their share with time [266], and our diets are clearly adapted to our pre-human (but pervading) basic
food taste types. Less exercise, better medical attention, longer lives and control of the sources of food
have modified our present-day diets. Culture, unproven ideas about food have been combined with
religious or social taboos, increased availability of different presentations of food and the culture-driven
extreme cult to taste. We are leaving starches to consume fats [266], and animal muscle protein and
collagen instead of aleurone-like plant reserves [267]. However, our digestive system and metabolic
energy handling systems were adapted to a quite different diet [268], and have not been able to maintain
the pace of change in eating habits occurring in the last centuries [266].Thus, a gap between digestive
system/nutrient utilization and diet composition exists and keeps growing. Glucose continues being
the main energy substrate, in spite of everything else, but its food form, ingestion, digestion, handling,
and oxidation necessarily change with the composition of the diet. However, that of Neanderthals
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showed little differences with our present day optimal diet types [269]. The periodicity, the ratio of
energy consumed (or needed) for a straightforward metabolic equilibrium versus that actually ingested
is a powerful destabilizing factor for an effective maintenance of metabolic equilibrium. Activity,
feeding, light and internal rhythms control our hormones and metabolism, helping us to adapt to
the variable conditions of the environment [270]. Probably this imbalance is a main cause of the MS
together to the fattening of the diet [271].
Considerable observation and experimentation have shown that amino-N should be a part of our
diet (in the range of 10–15% of ingested energy) [272]; and, also, that protein should be ever present in
our meals [273]. This implies that we also need to ingest an adequate supply of a few special amino
acids we cannot synthesize [274]. In parallel, we also know that, today, most humans are taking in too
much fat in their diets [275], often over 30% of all energy ingested [168,169]. An effect compounded by
the ingestion of energy above our physiological needs [276]. There is little quantitative analysis of
necessities, amounts and proportions, as explained in detail above. These approximate proportions are
quite different from those of all present-day apes, even more than most of the other primates [277].
This comparison should include our earlier human ancestors, usually short in protein, and even shorter
in lipids. Hints on the postulated hunter-gatherer ancestors feeding standards and behavior, and the
study of human dietary variability at present suggest that we are a remarkably adaptable species [278],
but in all cases, 3C takes priority over 2C, often with the help of the highest protein intake of all
primates [161,162]. Evidently, within the enormous variety of human groups and their adaptation
to all types of diet (the food available) and environmental conditions, it is expectable that a wide
variety will be found –also– in the differential use of the main nutrients; provoked, in general, through
epigenetic-driven adaptation to the foods available [279]. But most humans not living under extreme
conditions maintain diets which, despite the ample variability in foods and their proportions, provide
enough amino-N, 3C and 2C for healthy survival [267] (Figure 9).
The problems arise when the carefully established compensatory mechanisms for diets markedly
deviate from those of our ancestors, which result inoperative or deficient by excess of energy and,
especially, of some nutrients [199,205]. It seems that the Paleolithic (including ancient historical times)
physiological blueprint has evolved little in regulation, despite our admirable adaptation, to occupy
almost any ecological niche conceivable on Earth, and thus, diet-provoked “inflammatory” diseases
appear and remain unchecked [280].
Variable food supply, including in some cases its excesses and early death (for almost any
cause imaginable including diseases) shortened the lifespan of our predecessors already in historical
times [281]. Notwithstanding, in the present, our main health dangers seem to be related to our
“excessive” success in providing food and health care to a large proportion of humans, coupled with
an insufficiently fast evolutionary pace to let our bodies to adapt to this, so far, unique success in the
extension of a species mean lifespan and its consequences [282]. Enter the problems of aging: until
recently, a problem affecting a very small part of developed societies, that became a prime cause of
health, lifestyle and social problems because of the success in expanding our longevity [282,283].
Despite all that, we have not established (in times of plenty) an estimation of the magnitude of
3C-precursor nutrients we need to consume. Essentially the question is: do we need a minimum
intake of carbohydrate? [284]. Glucose is the main energy staple of our diet, and we base on 3C
substrates most of our metabolic function and regulation [36,47,48]. Instead, we centered our attention
on lipid (2C sources) [285–287], sugars as such [288], some minerals (e.g., salt), and, to a limited extent,
on protein [289]. It is unclear why our flag substrate, glucose, has not been given due importance
except as a marker of disease. However, the pervading idea of almost any food-derived nutrient
contributing effectively to our energy sustenance, with (almost) full substitution possibilities (as energy
fuels) between carbohydrates, fats, protein (and even alcohol) is deeply rooted. This belief would
render superfluous to analyze if there were a dietary minimum supply of 6C-3C substrates, in the
way we know that this minimum exists for amino-N and “loose” maximums are generally accepted
for lipids and alcohol (a toxic substance and “pure” 2C). From the data available, the quest for
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lowering glycaemia and reducing body weight [290] favor the use of low carbohydrate ketogenic
diets [291]. However, high-carbohydrate diets improve glucose metabolism [292] in healthy individuals,
and restriction of diet carbohydrates increases the risk of cardiovascular disorders, depending on the
diet energy and composition, especially in patients with disorders of glucose metabolism [293] (but
not in healthy individuals [294]). Not even glycaemia is better regulated in diabetics with excessive
dietary carbohydrate restriction [295]. The disarrangement provoked by the relative insufficiency of
carbohydrate in some “low-carbohydrate” diets depends, essentially on four factors:
(a) The metabolic “basal state” of the patients, since the results depend on gender, age and the
incidence of MS-related disorders.
(b) The overall energy intake with respect to the needs (or slimming goals) of the patient.
(c) A diet low in carbohydrates must get the energy from either protein or lipid, the proportion and
structure of these nutrients in the diet affects the incidence of lowering carbohydrate intake.
(d) The type of carbohydrate present in the diet and its food associations, essentially its relationship
to fiber and the mean molecular weight of the polysaccharides (including their digestibility and
effects on the microbiota).
The enormous variation of results, consequences, and effectiveness of the proposals coupled to the
soundness of the results from the data published, results in a near-impossibility to draw conclusions.
In addition, almost all diets studied have been applied for short periods of time to small numbers of
individuals with scant information even for the point a) and were done in ‘comparison’ with other
different types of diets. Even the reviews and meta-analyses could not draw clear consequences from
the huge amount of literature accrued on this question. There are too many factors to allow us to draw
safe conclusions from partial, incomplete and not superimposable data. To face this type of analysis,
a much-needed simplification is required, and reserve on the conclusions (and on their application to
people) must be observed.
Diet studies largely analyze the consumption of food items (a huge, varied and socially peculiar
group of products), which in addition have been cooked and mixed in varied proportions. This is
“reduced” to the nutrients they contain, but this may forsake aspects such as synergisms, food structure
(i.e., fiber), and the nature of the nutrient itself (fructose is as carbohydrate as amylose or a
resistant-starch, for instance, and collagen-rich squid is as protein as gluten). We know what is
eaten but not what is assimilated (the variable microbiota plays a critical role on this process). We need
more information on—at least—what is ingested along longer periods of time.
In any case, a multilateral approximation to the data known and the line of thought presented
here allows us to assume that a minimum (both in proportion and in absolute terms) of daily dietary
carbohydrate does exist [284], despite the possibility to substitute a large portion of the 6C intake by
other sources of 3C.
13. Perspectives, Conclusions, and an Urgent Call for More Quantitative Basic
Nutritional Studies
There is abundant literature but a dearth of information on diets. Unfortunately, when dealing
with the concept of diet industry, policy, fashion, absurdity and taste interact to produce dispersion,
unproven assertions, expanded private interests and outright lies, with—unfortunately—scant material
usable to advance scientific knowledge and improve the preservation of health. In most of the studies
available, an enormous variability in all the factors implied can be observed, and the formal and bona
fides results rarely go further than “hinting to,” with excessive room for interpretation and discordance
(or even actual overall relevance). The most recent and popular case in point is the Mediterranean
diet, which, in fact, has not been yet defined in nutritional terms [296] but has generated, nevertheless,
a considerable number of studies on its health benefits [297,298].
Why do relatively small modifications in diet may induce so deep changes or no changes at all
in functional parameters? We do not yet know enough to obtain a defendable and plausible answer.
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On one side, the nutritionists and dieticians usually analyze diets as a whole, use tables and measure
our anthropometric (and metabolic) data and detailed food intake to calculate the needs of nutrients
(translated to foods) to cover the energy expenditure, despite the fact that both factors are closely linked.
On the other side, a growing number of molecular biologists analyze the specific mechanisms of control
of endocrine and paracrine factors (largely those easily measurable), usually using isolated cells or
cultures, since this approach is not viable in most in vivo models. Both worlds of study are eons apart,
and keep publishing large amounts of deep, sometimes excellent studies on “new” signaling factors or
mechanisms, and the beneficial properties of some foods. Our scientific careers have passed through
different consecutive fashion periods: enzymes, hormone receptors, cyclic nucleotides, gene analysis,
cytokines, gene expression, microRNAs, gene modification, exosomes, stem cells, the transcendence of
microbiome, “virome/pandemic” etc. However, surprisingly nobody has devoted sufficient time and
funds to study such elementary “unknowns” as how “essential” are some amino acids (and which are
the paths of their complete catabolism in humans), how the excess N is eliminated (signals, pathways,
mechanisms, sites), or how much 6C (largely glycosyl monomers) we need to ingest daily? What is our
dependence of 3C as energy substrates? How is regulated the utilization of 2C/3C for energy (not only
in a type of cells, but overall)? Where does this take place? Why there are not enough quantitative
studies on how much lactate or glycerol uses the brain, muscle or heart? Is WAT a real storage depot or
a secondary supplier of 3C from excess glucose during hyperglycemia? Is insulin the main hormone
controlling use of glucose by tissues? What is the role of steroid hormones in the control of glycaemia?
and so on.
Perhaps the plausible results of studies trying to answer these questions do not sound “flashy”
enough for promotion, or perhaps they are not sufficiently “safe” to merit publication in “prestige”
journals, but we need to carry on “risky” studies to get the answers we need in order to understand
real problems such as how the substrates provided by the diet are distributed and used. We also need
them to understand and fight the negative effects of disorders that right now affect large portions of
Humankind. Right now, it is critical to obtain much more basic (and critical) knowledge to understand
the nature (and causes) of “inflammation” (obviously, not that defined by Celsus!) that is often used to
justify everything that is wrong in MS and related disorders.
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